Trial PaperDepressive DisordersAnxiety DisordersChronic PainPalliative & End-of-Life DistressLSD

LSD-assisted psychotherapy in patients with terminal cancer

This open-label study (n=60, 1973) with LSD and DPT for end-of-life anxiety related to terminal cancer found that patients significantly improved on mood/psychological scores (29% 'dramatic', 42% 'moderate', 23% 'unchanged', 6% 'decrement'). The study also found a non-significant trend towards lower narcotic medication use.

Authors

  • William Richards

Published

Pharmacopsychiatry
individual Study

Abstract

The paper describes the results of a clinical study exploring the potential of a complex psychotherapeutic program utilizing psychedelic compounds to alleviate the emotional and physical suffering of cancer patients. A total of 60 cancer patients participated in this experimental study. In 44 of these patients, LSD (200-500 p%per os) was administered as an adjunct to psychotherapy; in 19 patients, a new psychedelic compound, dipropyltryptamine (DPT) was administered (60-105 mg i.m.). Three of these patients received both LSD and DPT administered on different sessions. The therapeutic results were assessed by means of a rating scale reflecting the degree of the patients’ depression, psychological isolation, anxiety, difficulty in management, fear of death, and pain. The ratings were done by attending physicians, nurses, family members, LSD therapists and cotherapists, and independent raters. In addition, the amount of narcotics required in the management of the patient was measured before and after the psychedelic sessions. Systematic rating was carried out in a group of 31 cancer patients treated by LSD. The comparison of the means of individual ratings from pre- to posttreatment showed significant improvement in all the measured parameters for most of the raters. There was a definite reduction of the narcotic medication; it did not, however, reach the level of statistical significance. The pre- to post-treatment comparison of the global indexes used as gross indicators of the degree of emotional and physical distress, indicated that approximately 29 % of the patients showed dramatic improvement, and another 41.9 % moderate improvement, with 22.6 % essentially unchanged. In 6.4 % of the patients, global indexes showed a decrement in the posttherapy ratings.

Available with Blossom Pro

Research Summary of 'LSD-assisted psychotherapy in patients with terminal cancer'

Introduction

Stanislav and colleagues situate their work in the context of renewed clinical interest in the psychotherapeutic use of psychedelic drugs after early exploratory research in the 1950s and 1960s. Earlier reports suggested that LSD could produce profound subjective, 'psychedelic' experiences that sometimes led to reductions in anxiety and depression and to shifts in personal meaning and behaviour. A small number of prior clinical observations, notably by Kast and a single-case report by Cohen, had also suggested that LSD might lessen distress in patients in the late phases of terminal cancer, and these limited findings motivated the present clinical programme. This paper describes a clinical treatment series in which LSD (and, in some cases, DPT) was administered as an adjunct to brief but intensive psychotherapy for patients with terminal malignancy. The stated objectives were to use the psychedelic experience to reduce emotional distress (depression, anxiety, isolation), affect the patient's attitude toward dying, and, secondarily, to assess effects on pain and narcotic use. The authors also frame the work as preparatory to more controlled studies and note the particular methodological challenges of research in terminally ill populations.

Expert Research Summaries

Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.

Full Text PDF

Full Paper PDF

Create a free account to open full-text PDFs.

Study Details

Related Clinical Trial

Completed

Spring Grove / Maryland Psychiatric Research Center LSD-Assisted Psychotherapy Program for Terminal Cancer (Pahnke, Grof, Richards, Kurland ~1965–1972)

Uncontrolled open pilot clinical series of LSD- and DPT-assisted psychotherapy for terminal cancer patients conducted at Spring Grove State Hospital and the Maryland Psychiatric Research Center, Baltimore MD (~1965–1972; key investigators: Walter Pahnke, Stanislav Grof, William Richards, Albert Kurland). Total n~60 terminal cancer patients by July 1972 (P1 reports n=31 in earlier series; P2/P5 overlap with later cohort). Participants: referred for significant pain, depression, tension, anxiety or psychological isolation; estimated life expectancy ≥3 months. Sessions: single supervised psychedelic session (LSD 200–500 mcg IM, modal 300 mcg; or DPT 60–105 mg parenterally for shorter effect), with male-female therapist dyad, eyeshades, headphones, classical music, family involvement at termination. Preparatory psychotherapy ~6–12 h; integration psychotherapy beginning day after session. Outcome: Pahnke-Richards 7-domain observer rating (depression, isolation, fear of death, pain, etc. −6 to +6) by therapists, nurses, physicians, family; narcotic scale for analgesic use. Repeated sessions permitted if peak experience not achieved or symptoms recurred. No control arm; no registration (pre-registration era). Multiple publications report overlapping cohorts: Pahnke WN (1972, book chapter); Grof S et al. (Int Pharmacopsychiatry 1973, PMID 4140164); Kurland AA (J Psychoactive Drugs 1985, PMID 2418186).

Started
Type
interventional
Randomized
No
Registry ID
SPRING-GROVE-1965-1972-LSD-DPT-TERMINAL-CANCER-PROGRAM

Cited By (53)

Papers in Blossom that reference this study

Pilot study of psilocybin in patients with post-treatment lyme disease

Garcia-Romeu, A., Naudé, G. P., Rebman, A. W. et al. · Scientific Reports (2026)

Intact neurophysiological markers of death denial in long-term ayahuasca users

Dor-Ziderman, Y., David, J., Berkovich-Ohana, A. · Psychopharmacology (2025)

Structural neural plasticity evoked by rapid-acting antidepressant interventions

Liao, C., Dua, A. N., Wojtasiewicz, C. et al. · Nature Reviews Neuroscience (2024)

Potential analgesic effects of psychedelics on select chronic pain conditions: A survey study

Cavarra, M., Mason, N. L., Kuypers, K. P. C. et al. · European Journal of Pain (2023)

Classic psychedelics do not affect T cell and monocyte immune responses

Rudin, D., Areesanan, A., Liechti, M. E. et al. · Frontiers in Psychiatry (2023)

Lower-dose psycholytic therapy - A neglected approach

Passie, T., Guss, J., Kraehenmann, R. · Frontiers in Psychiatry (2022)

Show all 53 papers
Psychedelic-Assisted Psychotherapy-A Systematic Review of Associated Psychological Interventions

Cavarra, M., Falzone, A., Ramaekers, J. G. et al. · Frontiers in Psychology (2022)

Predictors and potentiators of psychedelic-occasioned mystical experiences

Gandy, S. · Journal of Psychedelic Studies (2022)

Psychedelics as Novel Therapeutics in Alzheimer’s Disease: Rationale and Potential Mechanisms

Garcia-Romeu, A., Darcy, S., Jackson, H. et al. · Current Topics in Behavioral Neurosciences (2021)

Improving cognitive functioning in major depressive disorder with psychedelics: a dimensional approach

Kuiperes, Z., Schreiber, R. · Neurobiology of Learning and Memory (2021)

Cancer Healthcare Workers' Perceptions toward Psychedelic-Assisted Therapy: A Preliminary Investigation

Reynolds, L. M, Stack, A., Akroyd, A., Sundram, F. et al. · International Journal of Environmental Research and Public Health (2021)

22 cited
Predicting changes in substance use following psychedelic experiences: natural language processing of psychedelic session narratives

Cox, D. J., Garcia-Romeu, A., Johnson, M. W. · The American Journal of Drug and Alcohol Abuse (2021)

Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern-era clinical studies

Andersen, K. A. A., Carhart-Harris, R. L., Nutt, D. J. et al. · Acta Psychiatrica Scandinavica (2020)

Acute subjective effects in LSD- and MDMA-assisted psychotherapy

Schmid, Y., Gasser, P., Oehen, P. et al. · Journal of Psychopharmacology (2020)

72 cited
A low dose of lysergic acid diethylamide decreases pain perception in healthy volunteers

Ramaekers, J. G., Hutten, N. P. W., Mason, N. L. et al. · Journal of Psychopharmacology (2020)

74 cited
Integrating psychotherapy and psychopharmacology: psychedelic-assisted psychotherapy and other combined treatments

Greenway, K. T., Garel, N., Jerome, L. et al. · Expert Review of Clinical Pharmacology (2020)

Isness: Using Multi-Person VR to Design Peak Mystical Type Experiences Comparable to Psychedelics

Glowacki, D. R., Wonnacott, M. D., Freire, R. et al. · Association for Computing Machinery (2020)

32 cited
Therapeutic Use of LSD in Psychiatry: A Systematic Review of Randomized-Controlled Clinical Trials

Fuentes, J. J., Fonseca, F., Elices, M. et al. · Frontiers in Psychiatry (2020)

292 cited
Psychedelics and music: neuroscience and therapeutic implications

Barrett, F. S., Preller, K. H., Kaelen, M. · International Review of Psychiatry (2018)

Individual Experiences in Four Cancer Patients Following Psilocybin-Assisted Psychotherapy

Ross, S., Malone, T. C., Mennenga, S. E. et al. · Frontiers in Pharmacology (2018)

Clinical interpretations of patient experience in a trial of psilocybin-assisted psychotherapy for alcohol use disorder

Bogenschutz, M. P., Podrebarac, S. K., Duane, J. H. et al. · Frontiers in Pharmacology (2018)

Serotonergic hallucinogens in the treatment of anxiety and depression in patients suffering from a life-threatening disease: A systematic review

Reiche, S., Hermle, L., Gutwinski, S. et al. · Progress in Neuro-Psychopharmacology and Biological Psychiatry (2018)

Two dose investigation of the 5-HT-agonist psilocybin on relative and global cerebral blood flow

Lewis, C. R., Preller, K. H., Kraehenmann, R. et al. · NeuroImage (2017)

74 cited
Clinical Applications of Hallucinogens: A Review

Garcia-Romeu, A., Kersgaard, B., Addy, P. H. · Experimental and Clinical Psychopharmacology (2016)

174 cited
Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA

Grob, C. S., Mithoefer, M. C., Brewerton, T. D. · Lancet Psychiatry (2016)

Psychedelics

Nichols, D. E. · Pharmacological Reviews (2016)

Acute effects of lysergic acid diethylamide in healthy subjects

Schmid, Y., Enzler, F., Gasser, P. et al. · Biological Psychiatry (2015)

Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction

Garcia-Romeu, A., Griffiths, R. R., Johnson, M. W. · Current Drug Abuse Reviews (2015)

Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study

Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A. et al. · Journal of Psychopharmacology (2015)

The Heffter Research Institute: Past and Hopeful Future

Nichols, D. E. · Journal of Psychoactive Drugs (2014)

16 cited
Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer

Grob, C. S., Danforth, A. L., Chopra, G. S. et al. · JAMA Psychiatry (2011)

The neurobiology of psychedelic drugs: implications for the treatment of mood disorders

Vollenweider, F. X., Kometer, M. · Nature Reviews Neuroscience (2010)

Human hallucinogen research: guidelines for safety

Johnson, M. W., Richards, W. A., Griffiths, R. R. · Journal of Psychopharmacology (2008)

Hallucinogens

Nichols, D. E. · Pharmacology and Therapeutics (2004)

Hallucinogenic drugs in psychiatric research and treatment: perspectives and prospects

Strassman, R. J. · Journal of Nervous and Mental Disease (1995)

93 cited
Adverse Reactions to Psychedelic Drugs - A Review of the Literature

Strassman, R. J. · Journal of Nervous and Mental Disease (1984)

273 cited

Your Personal Research Library

Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.